Inovio Pharmaceuticals Inc (INO)

[biovalidator]

The Immunotherapies and Vaccine Summit - 2014 - Boston, MA

Tuesday August 12
4:15 Engineering Cancer Immunotherapy One (DNA) Sequence at
a Time Mark Bagarazzi, M.D., CMO, Inovio Pharmaceuticals

Inovio is developing cancer immunotherapeutics by targeting both viral oncogenes (HPV E6, E7) as well as self proteins associated with cancer progression and metastases (PSA, PSMA, hTERT). Our common approach involves enhancing the delivery of optimized DNA sequences with the use of our proprietary in vivo electroporation system. We will share both preclinical and clinical data regarding several cancer indications.

Wednesday, August 13
7:45 am Breakfast Presentation (Sponsorship Opportunity Available)
or Morning Coffee
PREDICTING & ENHANCING HUMAN RESPONSE
8:25 Chairperson’s Opening Remarks
Mark Bagarazzi, M.D., CMO, Inovio Pharmaceutical

http://www.imvacs.com/uploadedFiles/ImVACS/Agenda/14/2014-IMT-Brochure.pdf

3:00 Synthetic DNA Vaccines for Difficult Targets
David B. Weiner, Ph.D., Professor, Pathology and Laboratory Medicine, Chair, Gene Therapy and Vaccine Program, CAMB, University of Pennsylvania Perelman School of Medicine
Through multiple improvements including synthetic plasmid optimization, genetic adjuvant technology further combined with enhanced EP delivery, we now report a platform for vaccine/immune therapeutic development with major relevance to human disease settings. These combined DNA approaches drive
immune responses similar or superior to live viral vector protocols in important model systems including HIV, HPV therapy, Influenza among others. We will
present data that illuminate specific features of these synthetic DNA vaccines and benchmark their performance in animal models and in human studies.